Ticker > Company >

Sudarshan Pharma Ind share price

Sudarshan Pharma Industries Ltd.

BSE: 543828 SECTOR: Pharmaceuticals & Drugs  19.29 K   10   0

31.48
-0.64 (-1.99%)
BSE: 03 Sep 4:00 PM

Price Summary

Today's High

₹ 31.5

Today's Low

₹ 31.48

52 Week High

₹ 53.5

52 Week Low

₹ 19.8

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

757.59 Cr.

Enterprise Value

930.16 Cr.

No. of Shares

24.07 Cr.

P/E

47.72

P/B

5.77

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  5.45

CASH

0.39 Cr.

DEBT

172.96 Cr.

Promoter Holding

57.39 %

EPS (TTM)

₹  0.66

Sales Growth

7.94%

ROE

13.28 %

ROCE

14.25%

Profit Growth

39.82 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year7.94%
3 Year12.06%
5 Year27.7%

Profit Growth

1 Year39.82%
3 Year44.59%
5 Year65.59%

ROE%

1 Year13.28%
3 Year11.58%
5 Year13.49%

ROCE %

1 Year14.25%
3 Year14.38%
5 Year15.29%

Debt/Equity

1.3566

Price to Cash Flow

21.7

Interest Cover Ratio

2.3335

CFO/PAT (5 Yr. Avg.)

0.350101530907523

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 57.39 0.00
Mar 2025 57.39 0.00
Sep 2024 57.39 0.00
Mar 2024 57.39 0.00
Sep 2023 57.39 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 44.5895426595088% for the Past 3 years.
  • The company has a high promoter holding of 57.39%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 25.2635724493713.

 Limitations

  • The company has shown a poor revenue growth of 12.0604354651073% for the Past 3 years.
  • The company is trading at a high PE of 47.72.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2025
Net Sales 142.31
Total Expenditure 132.03
Operating Profit 10.28
Other Income 1.42
Interest 5.71
Depreciation 0.79
Exceptional Items 0
Profit Before Tax 5.2
Tax 1.46
Profit After Tax 3.73
Adjusted EPS (Rs) 0.16

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 193.35 357.09 461.33 465.56 502.51
Total Expenditure 186.18 346.17 446.64 442.96 464
Operating Profit 7.17 10.92 14.69 22.6 38.5
Other Income 0.38 0.46 1.12 2.75 2.88
Interest 3.23 3.38 5.4 9.03 15.96
Depreciation 0.74 0.87 0.91 1.23 1.31
Exceptional Items 0 0 0 0 -2.82
Profit Before Tax 3.58 7.14 9.5 15.1 21.29
Tax 0.9 1.89 2.46 3.74 5.41
Net Profit 2.67 5.25 7.04 11.36 15.88
Adjusted EPS (Rs.) 0.28 0.54 0.29 0.47 0.66

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 9.55 9.75 24.07 24.07 24.07
Total Reserves 12.96 20.03 76.92 87.55 107.25
Borrowings 8.41 4.94 12.79 10.49 10.46
Other N/C liabilities 0.16 0.18 0.24 0.47 0.64
Current liabilities 68.13 102.61 118.46 162.27 257.98
Total Liabilities 99.21 137.51 232.47 284.84 400.4
Assets
Net Block 6.21 6.47 19.89 20.57 19.79
Capital WIP 0 0.54 0.01 1.88 6.04
Intangible WIP 0 0 0 0 0
Investments 0.09 0.1 12.44 15.44 32.01
Loans & Advances 5.4 0.94 1.62 1.75 4.48
Other N/C Assets 0 0 0 4.35 4.25
Current Assets 87.51 129.47 198.51 240.85 333.83
Total Assets 99.21 137.51 232.47 284.84 400.4
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 3.58 7.14 9.5 15.1 21.29
Adjustment 3.85 4.08 5.82 9.32 18.93
Changes in Assets & Liabilities -3.91 -13.15 -42 -12.62 -2.46
Tax Paid -0.84 -1.77 -2.11 -2.12 -2.84
Operating Cash Flow 2.67 -3.7 -28.79 9.69 34.91
Investing Cash Flow -1.35 -1.54 -25.65 -9.08 -20.24
Financing Cash Flow -1.44 4.31 65.93 -12.18 -14.41
Net Cash Flow -0.11 -0.93 11.48 -11.58 0.26

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Mar 2024% Sep 2024% Mar 2025% Jun 2025%
promoters 57.39 57.39 57.39 57.39 57.39
devangi hemal mehta 0.95 0.95 0.95 0.95 0.95
hemal v mehta huf - 0.68 0.68 0.68 0.68
hemal vasantrai mehta 26.60 26.60 26.60 26.60 26.60
jatin vasantrai mehta 0.07 0.07 0.07 0.07 0.07
namrata sachin mehta 0.68 0.68 0.68 0.68 0.68
sachin v mehta huf - 0.68 0.68 0.68 0.68
sachin vasantrai mehta 27.51 27.51 27.51 27.51 27.51
vasantrai ratilal mehta - - - - 0.20
vasantray ratilal mehta 0.14 0.20 0.20 0.20 -
hemal v mehta huf . 0.68 - - - -
indumati v mehta 0.07 - - - -
sachin v mehta huf . 0.68 - - - -
PARTICULARS Sep 2023% Mar 2024% Sep 2024% Mar 2025% Jun 2025%
investors 42.61 42.61 42.61 42.61 42.61
century india opportunity... - - - 2.39 3.49
coeus global opportunitie... - - 3.68 3.68 3.68
eminence global fund pcc-... - - 2.29 - 1.83
multitude growth funds li... - - - 5.52 5.02
nexpact limited - - - 1.34 1.38
north star opportunities ... - - - - 1.35
radiant global fund-class... - - 2.13 - 2.13
bishwanath prasad agrawal... - - 1.70 1.07 -
eminence global fund pcc ... - - - 1.83 -
radiant global fund - cla... - - - 2.13 -
ag dynamic funds limited - - 3.99 - -
gretex share broking limi... - 4.03 - - -
harish kumar rijhwani 3.09 2.70 - - -
indian infotech and softw... - 1.53 - - -
magicremedi private limit... 2.18 2.18 - - -
neelam sethia 1.13 1.13 - - -
prashant narinderlal chad... - 1.30 - - -
vishwamani tiwari huf - 2.24 - - -
gretex share broking priv... 3.28 - - - -
vishwamani tiwari huf . 2.24 - - - -
wasim javid dalal 1.91 - - - -
yashen jayesh savla 1.32 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2023

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q3FY25
Presentation H1FY24

Company News

Sudarshan Pharma Ind - Quaterly Results 14 Aug, 7:42 PM Sudarshan Pharma Ind - Quaterly Results 14 Aug, 7:42 PM Sudarshan Pharma Industries informs about trading window closure 30 Jun, 5:38 PM Sudarshan Pharma Industries gets nod to incorporate wholly-owned subsidiary in Canada 20 Jun, 10:41 AM Sudarshan Pharma Industries informs about newspaper publication 26 Apr, 12:31 PM Sudarshan Pharma Industries informs about press release 26 Apr, 12:21 PM Sudarshan Pharma gets nod to incorporate subsidiary in Poland 20 Feb, 10:59 AM Sudarshan Pharma Industries enters into Technology Transfer Agreement with Uttaranchal University 27 Jan, 9:58 AM Sudarshan Pharma Industries gets nod to acquire 100% stake in Cibachem 17 Jan, 10:41 AM Sudarshan Pharma Industries enters into Rent Agreement with Daundi Biological 7 Jan, 3:09 PM Sudarshan Pharma gets nod to acquire stake in Sudarshan Pharma Industries, Singapore 30 Nov, 12:43 PM Sudarshan Pharma Industries informs about acquisition 28 Aug, 12:53 PM Sudarshan Pharma Industries informs about business updates 7 Oct, 3:24 PM Sudarshan Pharma Industries incorporates subsidiary company 25 Aug, 12:59 PM Sudarshan Pharma Industries gets nod to incorporate subsidiary in Gujarat 18 Aug, 5:56 PM Sudarshan Pharma Industries to incorporate subsidiary in Gujarat 14 Aug, 9:39 AM Sudarshan Pharma Industries informs about business update 9 Aug, 2:12 PM Sudarshan Pharma Industries to subscribe 100% stake in Ratna Lifesciences 3 Aug, 10:07 AM Sudarshan Pharma Industries informs about certificate 20 Apr, 10:10 AM Sudarshan Pharma Industries coming with an IPO to raise upto Rs 50.10 crore 8 Mar, 10:56 AM

Sudarshan Pharma Ind Stock Price Analysis and Quick Research Report. Is Sudarshan Pharma Ind an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Sudarshan Pharma Ind. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Sudarshan Pharma Ind has a PE ratio of 47.7186599969683 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Sudarshan Pharma Ind has ROA of 4.634% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Sudarshan Pharma Ind has a Current ratio of 1.294.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Sudarshan Pharma Ind has a ROE of 13.2802%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Sudarshan Pharma Ind has a Debt to Equity ratio of 1.3566 which means that the company has low proportion of debt in its capital.

  • Sales growth: Sudarshan Pharma Ind has reported revenue growth of 7.9354% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Sudarshan Pharma Ind for the current financial year is 7.66212974359537%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Sudarshan Pharma Ind is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Sudarshan Pharma Ind is Rs 0.6597. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Sudarshan Pharma Ind in Ticker for free. Also, one can get the intrinsic value of Sudarshan Pharma Ind by using Valuation Calculators, which are available with a Finology ONE subscription. 

Sudarshan Pharma Ind FAQs

Q1. What is Sudarshan Pharma Ind share price today?
Ans: The current share price of Sudarshan Pharma Ind is Rs 31.48.

Q2. What is the market capitalisation of Sudarshan Pharma Ind?
Ans: Sudarshan Pharma Ind has a market capitalisation of Rs 757.59412276 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Sudarshan Pharma Ind?
Ans: The PE ratio of Sudarshan Pharma Ind is 47.7186599969683 and the P/B ratio of Sudarshan Pharma Ind is 5.77318075117371, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Sudarshan Pharma Ind share?
Ans: The 52-week high share price of Sudarshan Pharma Ind is Rs 53.5, and the 52-week low share price of Sudarshan Pharma Ind is Rs 19.8.

Q5. Does Sudarshan Pharma Ind pay dividends?
Ans: Currently, Sudarshan Pharma Ind does not pay dividends. Dividend yield of Sudarshan Pharma Ind is around 0%.

Q6. What are the face value and book value of Sudarshan Pharma Ind shares?
Ans: The face value of Sudarshan Pharma Ind shares is Rs 1, while the book value per share of Sudarshan Pharma Ind is around Rs 5.4528. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Sudarshan Pharma Ind?
Ans: Sudarshan Pharma Ind has a total debt of Rs 172.9554 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Sudarshan Pharma Ind?
Ans: The ROE of Sudarshan Pharma Ind is 13.2802% and ROCE of Sudarshan Pharma Ind is 14.2503%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Sudarshan Pharma Ind a good buy for the long term?
Ans: The Sudarshan Pharma Ind long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Sudarshan Pharma Ind undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Sudarshan Pharma Ind appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Sudarshan Pharma Ind’s financials?
Ans: You can review Sudarshan Pharma Ind’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Sudarshan Pharma Ind
X